AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
lesinurad 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| urate transporter inhibitors | 5075 | 878672-00-5 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Lesinurad reduces serum uric acid levels by inhibiting the function of transporter proteins involved in uric acid reabsorption in the kidney. Lesinurad inhibited the function of two apical transporters responsible for uric acid reabsorption, uric acid transporter 1 (URAT1) and organic anion transporter 4 (OAT4), with IC50 values of 7.3 and 3.7 μM, respectively. URAT1 is responsible for the majority of the reabsorption of filtered uric acid from the renal tubular lumen. OAT4 is a uric acid transporter associated with diuretic-induced hyperuricemia.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.20 | g | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Hosey CM, Chan R, Benet LZ |
| Vd (Volume of distribution) | 0.29 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 1.43 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.02 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 5 hours | Lombardo F, Berellini G, Obach RS |
| S (Water solubility) | 0.01 mg/mL | Bocci G, Oprea TI, Benet LZ |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,ERBB2,GRK2,GSK3B,ITK,JAK2,MAP2K6,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPK9,MAPKAPK2,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PIM2,PRKDC,STK33,SYK,TEK,TGFBR1,TTK,ZAP70 | 43 | |||
| kinase-selectivity-class | AXL,BRAF,CDK9,EIF2AK3,GRK2,MAPK7,STK33 | 7 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pld-class | Phospholipidosis risk class (1 = positive, 0 = negative) | 0 | High | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Feb. 18, 2016 | EMA | AstraZeneca AB | |
| Dec. 22, 2015 | FDA | ARDEA BIOSCIENCES INC |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | M04AB05 | MUSCULO-SKELETAL SYSTEM ANTIGOUT PREPARATIONS ANTIGOUT PREPARATIONS Preparations increasing uric acid excretion |
| MeSH PA | D006074 | Gout Suppressants |
| MeSH PA | D014528 | Uricosuric Agents |
| MeSH PA | D018501 | Antirheumatic Agents |
| FDA MoA | N0000190118 | Cytochrome P450 3A Inducers |
| FDA MoA | N0000192340 | Urate Transporter 1 Inhibitors |
| FDA EPC | N0000192341 | Urate Transporter 1 Inhibitor |
| CHEBI has role | CHEBI:35841 | uricosuric drug |
| CHEBI has role | CHEBI:35845 | gout suppressant |
Related Drugs by ATC class:
M04AB Preparations increasing uric acid excretion 5 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Hyperuricemia | indication | 35885006 | DOID:1920 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 3.5 | acidic |
| pKa2 | 1.05 | Basic |
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 200MG | ZURAMPIC | IRONWOOD PHARMS INC | N207988 | Dec. 22, 2015 | DISCN | TABLET | ORAL | 10183012 | Nov. 26, 2028 | TREATMENT OF HYPERURICEMIA ASSOCIATED WITH GOUT IN PATIENTS WHO HAVE NOT ACHIEVED TARGET SERUM URIC ACID LEVELS WITH A XANTHINE OXIDASE INHIBITOR ALONE |
| 200MG | ZURAMPIC | IRONWOOD PHARMS INC | N207988 | Dec. 22, 2015 | DISCN | TABLET | ORAL | 8283369 | Nov. 26, 2028 | ACHIEVING A THERAPEUTIC BENEFIT IN A SUBJECT WITH GOUT |
| 200MG | ZURAMPIC | IRONWOOD PHARMS INC | N207988 | Dec. 22, 2015 | DISCN | TABLET | ORAL | 8283369 | Nov. 26, 2028 | TREATMENT OF GOUT |
| 200MG;200MG | DUZALLO | IRONWOOD PHARMS INC | N209203 | Aug. 18, 2017 | DISCN | TABLET | ORAL | 10183012 | Nov. 26, 2028 | TREATMENT OF HYPERURICEMIA ASSOCIATED WITH GOUT IN PATIENTS WHO HAVE NOT ACHIEVED TARGET SERUM URIC ACID LEVELS WITH A MEDICALLY APPROPRIATE DAILY DOSE OF ALLOPURINOL ALONE |
| 200MG;200MG | DUZALLO | IRONWOOD PHARMS INC | N209203 | Aug. 18, 2017 | DISCN | TABLET | ORAL | 8283369 | Nov. 26, 2028 | TREATMENT OF HYPERURICEMIA ASSOCIATED WITH GOUT IN PATIENTS WHO HAVE NOT ACHIEVED TARGET SERUM URIC ACID LEVELS WITH A MEDICALLY APPROPRIATE DAILY DOSE OF ALLOPURINOL ALONE |
| 300MG;200MG | DUZALLO | IRONWOOD PHARMS INC | N209203 | Aug. 18, 2017 | DISCN | TABLET | ORAL | 10183012 | Nov. 26, 2028 | TREATMENT OF HYPERURICEMIA ASSOCIATED WITH GOUT IN PATIENTS WHO HAVE NOT ACHIEVED TARGET SERUM URIC ACID LEVELS WITH A MEDICALLY APPROPRIATE DAILY DOSE OF ALLOPURINOL ALONE |
| 300MG;200MG | DUZALLO | IRONWOOD PHARMS INC | N209203 | Aug. 18, 2017 | DISCN | TABLET | ORAL | 8283369 | Nov. 26, 2028 | TREATMENT OF HYPERURICEMIA ASSOCIATED WITH GOUT IN PATIENTS WHO HAVE NOT ACHIEVED TARGET SERUM URIC ACID LEVELS WITH A MEDICALLY APPROPRIATE DAILY DOSE OF ALLOPURINOL ALONE |
| 200MG | ZURAMPIC | IRONWOOD PHARMS INC | N207988 | Dec. 22, 2015 | DISCN | TABLET | ORAL | 8546437 | April 29, 2029 | TREATMENT OF HYPERURICEMIA |
| 200MG;200MG | DUZALLO | IRONWOOD PHARMS INC | N209203 | Aug. 18, 2017 | DISCN | TABLET | ORAL | 8546437 | April 29, 2029 | TREATMENT OF HYPERURICEMIA ASSOCIATED WITH GOUT IN PATIENTS WHO HAVE NOT ACHIEVED TARGET SERUM URIC ACID LEVELS WITH A MEDICALLY APPROPRIATE DAILY DOSE OF ALLOPURINOL ALONE |
| 300MG;200MG | DUZALLO | IRONWOOD PHARMS INC | N209203 | Aug. 18, 2017 | DISCN | TABLET | ORAL | 8546437 | April 29, 2029 | TREATMENT OF HYPERURICEMIA ASSOCIATED WITH GOUT IN PATIENTS WHO HAVE NOT ACHIEVED TARGET SERUM URIC ACID LEVELS WITH A MEDICALLY APPROPRIATE DAILY DOSE OF ALLOPURINOL ALONE |
| 200MG | ZURAMPIC | IRONWOOD PHARMS INC | N207988 | Dec. 22, 2015 | DISCN | TABLET | ORAL | 8084483 | Aug. 17, 2029 | REDUCTION OF SERUM URIC ACID LEVELS |
| 200MG;200MG | DUZALLO | IRONWOOD PHARMS INC | N209203 | Aug. 18, 2017 | DISCN | TABLET | ORAL | 8084483 | Aug. 17, 2029 | TREATMENT OF HYPERURICEMIA ASSOCIATED WITH GOUT IN PATIENTS WHO HAVE NOT ACHIEVED TARGET SERUM URIC ACID LEVELS WITH A MEDICALLY APPROPRIATE DAILY DOSE OF ALLOPURINOL ALONE |
| 300MG;200MG | DUZALLO | IRONWOOD PHARMS INC | N209203 | Aug. 18, 2017 | DISCN | TABLET | ORAL | 8084483 | Aug. 17, 2029 | TREATMENT OF HYPERURICEMIA ASSOCIATED WITH GOUT IN PATIENTS WHO HAVE NOT ACHIEVED TARGET SERUM URIC ACID LEVELS WITH A MEDICALLY APPROPRIATE DAILY DOSE OF ALLOPURINOL ALONE |
| 200MG | ZURAMPIC | IRONWOOD PHARMS INC | N207988 | Dec. 22, 2015 | DISCN | TABLET | ORAL | 8357713 | Dec. 22, 2029 | REDUCTION OF SERUM URIC ACID LEVELS |
| 200MG | ZURAMPIC | IRONWOOD PHARMS INC | N207988 | Dec. 22, 2015 | DISCN | TABLET | ORAL | 8357713 | Dec. 22, 2029 | TREATMENT OF GOUT |
| 200MG | ZURAMPIC | IRONWOOD PHARMS INC | N207988 | Dec. 22, 2015 | DISCN | TABLET | ORAL | 8357713 | Dec. 22, 2029 | TREATMENT OF HYPERURICEMIA |
| 200MG;200MG | DUZALLO | IRONWOOD PHARMS INC | N209203 | Aug. 18, 2017 | DISCN | TABLET | ORAL | 8357713 | Dec. 22, 2029 | TREATMENT OF HYPERURICEMIA ASSOCIATED WITH GOUT IN PATIENTS WHO HAVE NOT ACHIEVED TARGET SERUM URIC ACID LEVELS WITH A MEDICALLY APPROPRIATE DAILY DOSE OF ALLOPURINOL ALONE |
| 300MG;200MG | DUZALLO | IRONWOOD PHARMS INC | N209203 | Aug. 18, 2017 | DISCN | TABLET | ORAL | 8357713 | Dec. 22, 2029 | TREATMENT OF HYPERURICEMIA ASSOCIATED WITH GOUT IN PATIENTS WHO HAVE NOT ACHIEVED TARGET SERUM URIC ACID LEVELS WITH A MEDICALLY APPROPRIATE DAILY DOSE OF ALLOPURINOL ALONE |
| 200MG | ZURAMPIC | IRONWOOD PHARMS INC | N207988 | Dec. 22, 2015 | DISCN | TABLET | ORAL | 9216179 | Aug. 1, 2031 | COADMINISTERING WITH ALLOPURINOL TO REDUCE SERUM URIC ACID (SUA) BELOW 4 MG/DL; BELOW 6MG/DL IN PATIENTS HAVING URIC ACID DEPOSITS; AND/OR BELOW 6MG/DL WITH SUA INTRADAY CHANGE MORE THAN 50% AND/OR ADVERSE EVENT RATE LESS THAN 15% |
| 200MG;200MG | DUZALLO | IRONWOOD PHARMS INC | N209203 | Aug. 18, 2017 | DISCN | TABLET | ORAL | 9216179 | Aug. 1, 2031 | TREATMENT OF HYPERURICEMIA ASSOCIATED WITH GOUT IN PATIENTS WHO HAVE NOT ACHIEVED TARGET SERUM URIC ACID LEVELS WITH A MEDICALLY APPROPRIATE DAILY DOSE OF ALLOPURINOL ALONE |
| 300MG;200MG | DUZALLO | IRONWOOD PHARMS INC | N209203 | Aug. 18, 2017 | DISCN | TABLET | ORAL | 9216179 | Aug. 1, 2031 | TREATMENT OF HYPERURICEMIA ASSOCIATED WITH GOUT IN PATIENTS WHO HAVE NOT ACHIEVED TARGET SERUM URIC ACID LEVELS WITH A MEDICALLY APPROPRIATE DAILY DOSE OF ALLOPURINOL ALONE |
| 200MG | ZURAMPIC | IRONWOOD PHARMS INC | N207988 | Dec. 22, 2015 | DISCN | TABLET | ORAL | 9956205 | Dec. 28, 2031 | TREATMENT OF HYPERURICEMIA ASSOCIATED WITH GOUT IN PATIENTS WHO HAVE NOT ACHIEVED TARGET SERUM URIC ACID LEVELS WITH A XANTHINE OXIDASE INHIBITOR ALONE |
| 200MG;200MG | DUZALLO | IRONWOOD PHARMS INC | N209203 | Aug. 18, 2017 | DISCN | TABLET | ORAL | 9956205 | Dec. 28, 2031 | TREATMENT OF HYPERURICEMIA ASSOCIATED WITH GOUT IN PATIENTS WHO HAVE NOT ACHIEVED TARGET SERUM URIC ACID LEVELS WITH A MEDICALLY APPROPRIATE DAILY DOSE OF ALLOPURINOL ALONE |
| 300MG;200MG | DUZALLO | IRONWOOD PHARMS INC | N209203 | Aug. 18, 2017 | DISCN | TABLET | ORAL | 9956205 | Dec. 28, 2031 | TREATMENT OF HYPERURICEMIA ASSOCIATED WITH GOUT IN PATIENTS WHO HAVE NOT ACHIEVED TARGET SERUM URIC ACID LEVELS WITH A MEDICALLY APPROPRIATE DAILY DOSE OF ALLOPURINOL ALONE |
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Solute carrier family 22 member 12 | Transporter | INHIBITOR | IC50 | 5.14 | DRUG LABEL | DRUG LABEL | |||
| Solute carrier family 22 member 11 | Transporter | INHIBITOR | IC50 | 5.43 | DRUG LABEL |
External reference:
| ID | Source |
|---|---|
| D09921 | KEGG_DRUG |
| 4036022 | VANDF |
| CHEBI:90929 | CHEBI |
| A1AIL | PDB_CHEM_ID |
| CHEMBL2105720 | ChEMBL_ID |
| C000593471 | MESH_SUPPLEMENTAL_RECORD_UI |
| 7673 | IUPHAR_LIGAND_ID |
| DB11560 | DRUGBANK_ID |
| 1731031 | RXNORM |
| 237601 | MMSL |
| 31385 | MMSL |
| d08406 | MMSL |
| 016642 | NDDF |
| 715259003 | SNOMEDCT_US |
| 715745009 | SNOMEDCT_US |
| C3886073 | UMLSCUI |
| CHEMBL2105716 | ChEMBL_ID |
| 9345 | INN_ID |
| 53465279 | PUBCHEM_CID |
| 09ERP08I3W | UNII |
| 09ERP08I3W | INXIGHT DRUGS |
Pharmaceutical products:
None